Bocidelpar

N/A

Report date: 2024/06/12 20:00:37
NME

Base Information

Drug NameBocidelpar
Drug Alias NameMTB-1A-0367MA-0211ASP-0367
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor delta modulators
TargetsPeroxisome proliferator-activated receptor delta
Therapy Area/IndicationsRenal InsufficiencyHepatic InsufficiencyMuscular Dystrophy, Duchenne +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Global Development Inc
Inactive CompaniesAstellas Pharma Inc
Active IndicationsRenal InsufficiencyHepatic Insufficiency
Inactive IndicationsMuscular Dystrophy, DuchenneMitochondrial Myopathies

Other Information

ATC CodeN/A
Related LinksN/A